title: Dorzolamide-induced immune thrombocytopenia: a case report and literature review.
abstract: OBJECTIVE
  To report a severe case of dorzolamide-induced immune thrombocytopenia, to review the literature on this topic, and to draw attention to the serious potential side effects of this topical sulfonamide.
  
  
  METHODS
  An 83-year-old man with primary open-angle glaucoma in both eyes who was taking topical dorzolamide therapy for 3.5 years developed a severe thrombocytopenia (10,000 platelets/microL). The amount of platelets was not influenced by prednisone therapy but increased rapidly to 100,000/microL after the withdrawal of dorzolamide.
  
  
  METHODS
  Although the potential capacity of sulfonamides to induce thrombocytopenia is well known, no case of dorzolamide-induced immune thrombocytopenia was published in the medical literature until July 2000.
  
  
  CONCLUSIONS
  Considering the possible severe side effects that can be induced by topical dorzolamide 2%, ophthalmologists should carefully evaluate during the medical history of their patients the risk of sensitivity to sulfonamides.
authors.affiliation: Department of Ophthalmology, University Hospital, Zurich, Switzerland.
authors.forename: X D
authors.initials: XD
authors.lastname: Martin
authors.forename: M
authors.initials: M
authors.lastname: Danese
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005902:Glaucoma, Open-Angle / Q000188:drug therapy; D006801:Humans; D008297:Male; D010976:Platelet Count; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D013876:Thiophenes / Q000009:adverse effects* / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced*
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide